Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Gene-targeting approaches for movement disorders: recent advances.

Kaplitt MG.

Curr Opin Neurol. 2019 Aug;32(4):566-570. doi: 10.1097/WCO.0000000000000719.

PMID:
31232714
2.

Magnetic resonance-guided focused ultrasound for ablation of mesial temporal epilepsy circuits: modeling and theoretical feasibility of a novel noninvasive approach.

Parker WE, Weidman EK, Chazen JL, Niogi SN, Uribe-Cardenas R, Kaplitt MG, Hoffman CE.

J Neurosurg. 2019 Jun 14:1-8. doi: 10.3171/2019.4.JNS182694. [Epub ahead of print]

PMID:
31200385
3.

Impact of skull density ratio on efficacy and safety of magnetic resonance-guided focused ultrasound treatment of essential tremor.

D'Souza M, Chen KS, Rosenberg J, Elias WJ, Eisenberg HM, Gwinn R, Taira T, Chang JW, Lipsman N, Krishna V, Igase K, Yamada K, Kishima H, Cosgrove R, Rumià J, Kaplitt MG, Hirabayashi H, Nandi D, Henderson JM, Butts Pauly K, Dayan M, Halpern CH, Ghanouni P.

J Neurosurg. 2019 Apr 26:1-6. doi: 10.3171/2019.2.JNS183517. [Epub ahead of print]

PMID:
31026836
4.

Repeat magnetic resonance imaging-guided focused ultrasound thalamotomy for recurrent essential tremor: case report and review of MRI findings.

Weidman EK, Kaplitt MG, Strybing K, Chazen JL.

J Neurosurg. 2019 Jan 25:1-6. doi: 10.3171/2018.10.JNS181721. [Epub ahead of print]

PMID:
30684946
5.

Correction to: Cranial MR-guided Focused Ultrasound for Essential Tremor : Technical Considerations and Image Guidance.

Chazen JL, Stradford T, Kaplitt MG.

Clin Neuroradiol. 2019 Jun;29(2):359. doi: 10.1007/s00062-018-0751-8.

PMID:
30552474
6.

Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity.

Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, Dhawan V, Ma Y, Small M, Feigin A, During MJ, Kaplitt MG, Eidelberg D.

Sci Transl Med. 2018 Nov 28;10(469). pii: eaau0713. doi: 10.1126/scitranslmed.aau0713.

PMID:
30487248
7.

Cranial MR-guided Focused Ultrasound for Essential Tremor : Technical Considerations and Image Guidance.

Levi Chazen J, Stradford T, Kaplitt MG.

Clin Neuroradiol. 2019 Jun;29(2):351-357. doi: 10.1007/s00062-018-0709-x. Epub 2018 Jul 25. Erratum in: Clin Neuroradiol. 2018 Dec 14;:.

PMID:
30046918
8.

Safe and stable noninvasive focal gene delivery to the mammalian brain following focused ultrasound.

Stavarache MA, Petersen N, Jurgens EM, Milstein ER, Rosenfeld ZB, Ballon DJ, Kaplitt MG.

J Neurosurg. 2018 Apr 27;130(3):989-998. doi: 10.3171/2017.8.JNS17790.

PMID:
29701544
9.

Neurological adverse event profile of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor.

Fishman PS, Elias WJ, Ghanouni P, Gwinn R, Lipsman N, Schwartz M, Chang JW, Taira T, Krishna V, Rezai A, Yamada K, Igase K, Cosgrove R, Kashima H, Kaplitt MG, Tierney TS, Eisenberg HM.

Mov Disord. 2018 May;33(5):843-847. doi: 10.1002/mds.27401. Epub 2018 Apr 27.

PMID:
29701263
10.

AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.

Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C, Pey E, Zhao L, Ricart Arbona RJ, Monette S, Dyke JP, Ballon DJ, Kaminsky SM, Sondhi D, Petsko GA, Paul SM, Crystal RG.

Hum Gene Ther Clin Dev. 2018 Mar;29(1):24-47. doi: 10.1089/humc.2017.231. Epub 2018 Mar 13.

11.

Characterization of early-onset motor deficits in the Pink1-/- mouse model of Parkinson disease.

Kelm-Nelson CA, Brauer AFL, Barth KJ, Lake JM, Sinnen MLK, Stehula FJ, Muslu C, Marongiu R, Kaplitt MG, Ciucci MR.

Brain Res. 2018 Feb 1;1680:1-12. doi: 10.1016/j.brainres.2017.12.002. Epub 2017 Dec 8.

12.

Clinical improvement associated with targeted interruption of the cerebellothalamic tract following MR-guided focused ultrasound for essential tremor.

Chazen JL, Sarva H, Stieg PE, Min RJ, Ballon DJ, Pryor KO, Riegelhaupt PM, Kaplitt MG.

J Neurosurg. 2018 Aug;129(2):315-323. doi: 10.3171/2017.4.JNS162803. Epub 2017 Oct 20.

PMID:
29053074
13.

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.

Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A.

JCI Insight. 2017 Apr 6;2(7):e90133. doi: 10.1172/jci.insight.90133.

14.

Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.

Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH, Gupta A, Tsiouris AJ, Kovanlikaya I, Chiang GC, Weinsaft JW, Tanenbaum L, Chen W, Zhu W, Chang S, Lou M, Kopell BH, Kaplitt MG, Devos D, Hirai T, Huang X, Korogi Y, Shtilbans A, Jahng GH, Pelletier D, Gauthier SA, Pitt D, Bush AI, Brittenham GM, Prince MR.

J Magn Reson Imaging. 2017 Oct;46(4):951-971. doi: 10.1002/jmri.25693. Epub 2017 Mar 10. Review.

15.

Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.

Marongiu R, Arango-Lievano M, Francardo V, Morgenstern P, Zhang X, Cenci MA, Svenningsson P, Greengard P, Kaplitt MG.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1423-8. doi: 10.1073/pnas.1524387113. Epub 2016 Jan 19.

16.

p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.

Schintu N, Zhang X, Alvarsson A, Marongiu R, Kaplitt MG, Greengard P, Svenningsson P.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1429-34. doi: 10.1073/pnas.1524303113. Epub 2016 Jan 19.

17.

Opposing roles for serotonin in cholinergic neurons of the ventral and dorsal striatum.

Virk MS, Sagi Y, Medrihan L, Leung J, Kaplitt MG, Greengard P.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):734-9. doi: 10.1073/pnas.1524183113. Epub 2016 Jan 5.

18.

The tumor suppressor PTEN regulates motor responses to striatal dopamine in normal and Parkinsonian animals.

Stavarache MA, Musatov S, McGill M, Vernov M, Kaplitt MG.

Neurobiol Dis. 2015 Oct;82:487-494. doi: 10.1016/j.nbd.2015.07.013. Epub 2015 Jul 29.

PMID:
26232589
19.

[Depression and addiction comorbidity: towards a common molecular target?].

Arango-Lievano M, Kaplitt MG.

Med Sci (Paris). 2015 May;31(5):546-50. doi: 10.1051/medsci/20153105017. Epub 2015 Jun 9. Review. French.

20.

The Nucleus Accumbens: A Comprehensive Review.

Salgado S, Kaplitt MG.

Stereotact Funct Neurosurg. 2015;93(2):75-93. Epub 2015 Feb 18.

21.

Nitric oxide regulates synaptic transmission between spiny projection neurons.

Sagi Y, Heiman M, Peterson JD, Musatov S, Scarduzio M, Logan SM, Kaplitt MG, Surmeier DJ, Heintz N, Greengard P.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17636-41. doi: 10.1073/pnas.1420162111. Epub 2014 Nov 20. Erratum in: Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1811.

22.

Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling.

Gürsel DB, Banu MA, Berry N, Marongiu R, Burkhardt JK, Kobylarz K, Kaplitt MG, Rafii S, Boockvar JA.

J Neurooncol. 2015 Jan;121(1):19-29. doi: 10.1007/s11060-014-1602-3. Epub 2014 Oct 26.

PMID:
25344882
23.

Network modulation following sham surgery in Parkinson's disease.

Ko JH, Feigin A, Mattis PJ, Tang CC, Ma Y, Dhawan V, During MJ, Kaplitt MG, Eidelberg D.

J Clin Invest. 2014 Aug;124(8):3656-66. doi: 10.1172/JCI75073. Epub 2014 Jul 18.

24.

Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease.

Plotkin JL, Day M, Peterson JD, Xie Z, Kress GJ, Rafalovich I, Kondapalli J, Gertler TS, Flajolet M, Greengard P, Stavarache M, Kaplitt MG, Rosinski J, Chan CS, Surmeier DJ.

Neuron. 2014 Jul 2;83(1):178-88. doi: 10.1016/j.neuron.2014.05.032.

25.

Cell-type specific expression of p11 controls cocaine reward.

Arango-Lievano M, Schwarz JT, Vernov M, Wilkinson MB, Bradbury K, Feliz A, Marongiu R, Gelfand Y, Warner-Schmidt J, Nestler EJ, Greengard P, Russo SJ, Kaplitt MG.

Biol Psychiatry. 2014 Nov 15;76(10):794-801. doi: 10.1016/j.biopsych.2014.02.012. Epub 2014 Feb 26.

26.

Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function.

Orlin A, Sondhi D, Witmer MT, Wessel MM, Mezey JG, Kaminsky SM, Hackett NR, Yohay K, Kosofsky B, Souweidane MM, Kaplitt MG, D'Amico DJ, Crystal RG, Kiss S.

PLoS One. 2013 Aug 28;8(8):e73128. doi: 10.1371/journal.pone.0073128. eCollection 2013.

27.

Spinal cord stimulation for vegetative state: is this ready for prime time?

Kaplitt MG.

Stereotact Funct Neurosurg. 2013;91(5):288-9. doi: 10.1159/000348272. Epub 2013 Jun 22. No abstract available.

28.

Improved subthalamic nucleus depiction with quantitative susceptibility mapping.

Liu T, Eskreis-Winkler S, Schweitzer AD, Chen W, Kaplitt MG, Tsiouris AJ, Wang Y.

Radiology. 2013 Oct;269(1):216-23. doi: 10.1148/radiol.13121991. Epub 2013 May 14.

29.

Gene therapy for psychiatric disorders.

Gelfand Y, Kaplitt MG.

World Neurosurg. 2013 Sep-Oct;80(3-4):S32.e11-8. doi: 10.1016/j.wneu.2012.12.028. Epub 2012 Dec 23. Review.

PMID:
23268195
30.

Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.

Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, Kaplitt MG, Kosofsky B, Yohay K, Ballon D, Dyke J, Kaminksy SM, Hackett NR, Crystal RG.

Hum Gene Ther Methods. 2012 Oct;23(5):324-35. doi: 10.1089/hgtb.2012.120. Epub 2012 Nov 6.

31.

Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging.

Dyke JP, Sondhi D, Voss HU, Shungu DC, Mao X, Yohay K, Worgall S, Hackett NR, Hollmann C, Yeotsas ME, Jeong AL, Van de Graaf B, Cao I, Kaminsky SM, Heier LA, Rudser KD, Souweidane MM, Kaplitt MG, Kosofsky B, Crystal RG, Ballon D.

AJNR Am J Neuroradiol. 2013 Apr;34(4):884-9. doi: 10.3174/ajnr.A3297. Epub 2012 Oct 4.

32.

Bidirectional regulation of emotional memory by 5-HT1B receptors involves hippocampal p11.

Eriksson TM, Alvarsson A, Stan TL, Zhang X, Hascup KN, Hascup ER, Kehr J, Gerhardt GA, Warner-Schmidt J, Arango-Lievano M, Kaplitt MG, Ogren SO, Greengard P, Svenningsson P.

Mol Psychiatry. 2013 Oct;18(10):1096-105. doi: 10.1038/mp.2012.130. Epub 2012 Oct 2.

33.

Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior.

Warner-Schmidt JL, Schmidt EF, Marshall JJ, Rubin AJ, Arango-Lievano M, Kaplitt MG, Ibañez-Tallon I, Heintz N, Greengard P.

Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11360-5. doi: 10.1073/pnas.1209293109. Epub 2012 Jun 25.

34.

Improved sequence learning with subthalamic nucleus deep brain stimulation: evidence for treatment-specific network modulation.

Mure H, Tang CC, Argyelan M, Ghilardi MF, Kaplitt MG, Dhawan V, Eidelberg D.

J Neurosci. 2012 Feb 22;32(8):2804-13. doi: 10.1523/JNEUROSCI.4331-11.2012.

35.

Adeno-associated viral gene delivery in neurodegenerative disease.

Morgenstern PF, Marongiu R, Musatov SA, Kaplitt MG.

Methods Mol Biol. 2011;793:443-55. doi: 10.1007/978-1-61779-328-8_29.

PMID:
21913118
36.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A.

Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.

PMID:
21419704
37.

Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens.

Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, Vernov M, Stavarache M, Musatov S, Flajolet M, Svenningsson P, Greengard P, Kaplitt MG.

Sci Transl Med. 2010 Oct 20;2(54):54ra76. doi: 10.1126/scitranslmed.3001079. Erratum in: Sci Transl Med. 2010 Oct 27;2(55):55er3. Arango-Llievano, Margarita [corrected to Arango-Lievano, Margarita]; Stavarche, Mihaela [corrected to Stavarache, Mihaela].

38.

Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations.

Souweidane MM, Fraser JF, Arkin LM, Sondhi D, Hackett NR, Kaminsky SM, Heier L, Kosofsky BE, Worgall S, Crystal RG, Kaplitt MG.

J Neurosurg Pediatr. 2010 Aug;6(2):115-22. doi: 10.3171/2010.4.PEDS09507.

39.

Parkinson disease: Another player in gene therapy for Parkinson disease.

Kaplitt MG.

Nat Rev Neurol. 2010 Jan;6(1):7-8. doi: 10.1038/nrneurol.2009.214. No abstract available.

PMID:
20057491
40.

Novel mitochondrial substrates of omi indicate a new regulatory role in neurodegenerative disorders.

Johnson F, Kaplitt MG.

PLoS One. 2009 Sep 18;4(9):e7100. doi: 10.1371/journal.pone.0007100.

41.

Gene therapy clinical trials in the human brain. Protocol development and review of current applications.

Kaplitt MG.

Front Neurol Neurosci. 2009;25:180-188. doi: 10.1159/000209498. Epub 2009 Mar 19. Review. No abstract available.

PMID:
19478520
42.

Clinical trials of surgical devices for neurological disorders.

Kaplitt MG, Barbaro N.

Front Neurol Neurosci. 2009;25:174-179. doi: 10.1159/000209497. Epub 2009 Mar 19. No abstract available.

PMID:
19478519
43.

Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET.

Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt MG, Eidelberg D.

J Neurosurg. 2009 Jun;110(6):1278-82. doi: 10.3171/2008.12.JNS08991.

PMID:
19301972
44.

PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease.

Liu W, Vives-Bauza C, Acín-Peréz- R, Yamamoto A, Tan Y, Li Y, Magrané J, Stavarache MA, Shaffer S, Chang S, Kaplitt MG, Huang XY, Beal MF, Manfredi G, Li C.

PLoS One. 2009;4(2):e4597. doi: 10.1371/journal.pone.0004597. Epub 2009 Feb 26.

45.

Viral vector-mediated overexpression of estrogen receptor-alpha in striatum enhances the estradiol-induced motor activity in female rats and estradiol-modulated GABA release.

Schultz KN, von Esenwein SA, Hu M, Bennett AL, Kennedy RT, Musatov S, Toran-Allerand CD, Kaplitt MG, Young LJ, Becker JB.

J Neurosci. 2009 Feb 11;29(6):1897-903. doi: 10.1523/JNEUROSCI.4647-08.2009.

46.

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.

Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, Dyke JP, Ballon D, Heier L, Greenwald BM, Christos P, Mazumdar M, Souweidane MM, Kaplitt MG, Crystal RG.

Hum Gene Ther. 2008 May;19(5):463-74. doi: 10.1089/hum.2008.022.

PMID:
18473686
47.

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, Eidelberg D.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19559-64. Epub 2007 Nov 27.

48.

Progress and prospects: gene therapy clinical trials (part 1).

Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S.

Gene Ther. 2007 Oct;14(20):1439-47. Review. Erratum in: Gene Ther. 2007 Dec;14(24):1754. multiple author names added.

PMID:
17909539
49.

Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.

Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, Mao X, Kosofsky B, Kaplitt MG, Souweidane MM, Sondhi D, Hackett NR, Hollmann C, Crystal RG.

Neurology. 2007 Aug 7;69(6):521-35.

PMID:
17679671
50.

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ.

Lancet. 2007 Jun 23;369(9579):2097-105.

PMID:
17586305

Supplemental Content

Loading ...
Support Center